Thus, this study indicates that anti-CD20–IFNα eradicates B-cell lymphoma by employing tumor cells as APCs to reactivate tumor-infiltrating CD8+ T cells and synergizing with anti-PD-L1 treatment. The gene discussed is IFNA1; the disease is B-cell non-Hodgkin lymphoma.